Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombosis and embolism

E H Horn1

  • 1University Hospital, Nottingham, UK.

Bailliere'S Clinical Obstetrics and Gynaecology
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Preventing venous thromboembolism in obstetric patients is crucial. Anticoagulant prophylaxis, particularly heparin during pregnancy, should target high-risk groups, but more research is needed, especially in the puerperium.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Controversy of non-steroidal anti-inflammatory drugs and intracranial surgery: et ne nos inducas in tentationem?

British journal of anaesthesia·2011
Same author

Original article: Effects of Raised Extracellular Magnesium on Platelet Reactivity.

Platelets·2010
Same author

The effect on platelet behaviour of treatment with atenolol and the combination of atenolol and nifedipine in healthy volunteers.

Platelets·2010
Same author

Platelets in normal and hypertensive pregnancy.

Platelets·2010
Same author

Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.

Methods and findings in experimental and clinical pharmacology·2007
Same author

Evidence of in vivo platelet activation during heparin anticoagulation in pregnancy for prophlaxis or treatment of thromboembolism.

African journal of medicine and medical sciences·2003
Same journal

The use of gonadotrophin-releasing hormone antagonists in polycystic ovarian disease.

Bailliere's clinical obstetrics and gynaecology·2000
Same journal

Use of luteinizing hormone releasing hormone agonists in polycystic ovary syndrome.

Bailliere's clinical obstetrics and gynaecology·2000
Same journal

Epithelial ovarian cancer, infertility and induction of ovulation: possible pathogenesis and updated concepts.

Bailliere's clinical obstetrics and gynaecology·2000
Same journal

Complications of ovarian stimulation.

Bailliere's clinical obstetrics and gynaecology·2000
Same journal

Adverse effects of luteinizing hormone on fertility: fact or fantasy.

Bailliere's clinical obstetrics and gynaecology·2000
Same journal

Surgical management of polycystic ovarian syndrome.

Bailliere's clinical obstetrics and gynaecology·2000
See all related articles

Area of Science:

  • Obstetrics and Gynecology
  • Hematology
  • Pharmacology

Background:

  • Deep vein thrombosis and pulmonary embolism pose significant risks in obstetric patients.
  • Anticoagulant use during pregnancy presents maternal and fetal challenges.
  • Limited controlled clinical trials hinder optimal management strategies.

Purpose of the Study:

  • To review current recommendations for preventing venous thromboembolism in pregnancy and the puerperium.
  • To identify optimal anticoagulant prophylaxis strategies for obstetric patients.
  • To highlight the need for further clinical research in this area.

Main Methods:

  • Review of existing data and clinical guidelines on anticoagulant prophylaxis in pregnancy.
  • Analysis of the efficacy and safety of different anticoagulant agents.

Related Experiment Videos

  • Identification of high-risk patient groups for targeted prophylaxis.

    • Main Results:

    • Anticoagulant prophylaxis is the preferred approach for managing venous thromboembolism risks.
    • Heparin is recommended for venous thrombosis prophylaxis during pregnancy.
    • Warfarin remains effective for preventing systemic embolism in patients with artificial cardiac valves.
    • Prophylactic measures for venous thrombosis appear underutilized postpartum.

    Conclusions:

    • Targeted anticoagulant prophylaxis for high-risk obstetric patients is recommended.
    • Heparin is the preferred agent during pregnancy, while warfarin is crucial for specific cardiac conditions.
    • There is an urgent need for controlled clinical studies to optimize venous thromboembolism prophylaxis in the obstetric population, particularly during the puerperium.